Ipamorelin: Published Research

Introduction

Ipamorelin (NNC 26-0161) is a synthetic pentapeptide GHS-R1a agonist that has been the subject of peer-reviewed research since its initial characterization in 1998. The body of published literature spans in vitro cell assays, in vivo rodent and swine models, ex vivo tissue preparations, pharmacokinetic studies, and a published phase 2 randomized controlled trial in humans. The compound's defining pharmacological characteristic — selective GH release without co-stimulation of ACTH or cortisol at pharmacological concentrations in preclinical models [1] — generated a multidisciplinary research corpus covering pituitary biology, bone physiology, gastrointestinal pharmacology, and endocrinology. The receptor pharmacology underlying these findings is covered in detail in the ipamorelin mechanism of action article. This article provides a bibliographic summary of primary studies organized by research domain, with attention to methodology and reported findings. All findings are attributed to their source studies and no meta-analytic conclusions are drawn.

Methodology Types Across the Research Corpus

The ipamorelin research literature employs several distinct experimental approaches:

In vitro pituitary cell assays — studies using primary rat anterior pituitary cell cultures to measure GH release in response to ipamorelin and comparator peptides. This approach characterizes direct secretagogue potency and receptor-mediated effects at the somatotroph level, isolated from systemic feedback.

In vivo rodent and swine studies — acute and chronic administration in anesthetized or conscious rats and swine, measuring circulating GH, IGF-1, and other hormone levels. Conscious swine models are considered more physiologically relevant than rodent models for GH secretory pulsatility characterization. Rodent GH secretory physiology differs substantially from human patterns, which is a recognized consideration when extrapolating findings.

Ex vivo tissue preparations — isolated organ preparations (gastric strips, pancreatic fragments) used to examine ipamorelin effects on contractility or secretion under controlled pharmacological conditions.

Pharmacokinetic studies — measurement of plasma concentration-time profiles following administration by various routes in rodents, characterizing absorption, clearance, and excretion parameters.

Randomized controlled clinical trials — double-blind, placebo-controlled human studies examining safety and efficacy on predefined endpoints in patient populations.

Summary of Studies

Foundational Characterization: GH Selectivity (1998)

The landmark study by Raun and colleagues at Novo Nordisk (1998) characterized ipamorelin as a novel pentapeptide with high in vitro and in vivo GH-releasing potency comparable to GHRP-6 [1]. In primary rat pituitary cells, ipamorelin released GH with an ED₅₀ in the low nanomolar range. In conscious swine — a model considered more physiologically relevant than rodent models for GH secretory pattern characterization — robust GH pulses were observed following ipamorelin administration.

The study's defining finding was hormonal selectivity: at doses more than 200-fold above the in vivo ED₅₀ for GH release, ipamorelin did not significantly affect ACTH, cortisol, FSH, LH, prolactin, or TSH plasma levels in the swine model [1]. The authors concluded that ipamorelin represented "the first selective growth hormone secretagogue" — a classification reflected throughout subsequent literature that cited this selectivity profile as the compound's primary pharmacological distinction.

Structure-Activity Relationships and Pharmacokinetics (1998)

Ankersen and colleagues (1998) described SAR work derived from the ipamorelin scaffold, reporting that backbone modifications and incorporation of a peptidomimetic fragment produced a series of GHS compounds with retained potency and altered physicochemical properties [2]. The authors noted that ipamorelin served as a productive structural template for generating further GHS diversity, establishing the compound's scientific utility beyond its own pharmacological profile.

In the same year, Johansen and colleagues characterized comparative pharmacokinetics of ipamorelin alongside GHRP-2 and GHRP-6 in rats, reporting that ipamorelin displayed systemic plasma clearance approximately five-fold lower than GHRP-6 and was primarily eliminated via urinary rather than biliary excretion [3]. The authors also evaluated nasal absorption, contributing to the multi-route pharmacokinetic characterization of the compound.

Bone Growth Effects in Rats (1999)

Johansen and colleagues (1999) investigated the effects of ipamorelin on longitudinal bone growth in rats using tibia bone growth rate measurements over a 15-day administration period [4]. The study reported that ipamorelin administration was associated with a dose-dependent increase in longitudinal bone growth rate and body weight gain in the rodent model. The authors observed that the bone growth rate response was consistent with GH-mediated downstream actions and noted that the findings motivated investigation of ipamorelin in GH-axis research contexts [4].

Glucocorticoid Interaction Study (1999)

Malmlöf and colleagues (1999) examined whether synthetic glucocorticoid methylprednisolone suppressed GH responsiveness to ipamorelin in rats [5]. The study reported that methylprednisolone-treated animals maintained acute GH responses to both ipamorelin and GHRH, suggesting that glucocorticoid treatment did not abrogate the GH-secretory pathway through which ipamorelin acts. In a second experimental arm using surgically implanted chronic catheters, repeated ipamorelin administration alongside methylprednisolone was associated with attenuated body weight loss compared to methylprednisolone alone, alongside elevated IGF-1 levels [5]. The authors presented these findings as exploratory preclinical observations.

Somatotroph Biology: Chronic Exposure Study (2002)

Jiménez-Reina and colleagues (2002) investigated morphological and functional changes in pituitary somatotroph cells in young female rats following 21 days of ipamorelin administration [6]. The study employed immunohistochemical and morphometric analysis of pituitary tissue alongside in vitro GH release assays from cultured cells harvested from treated animals. Findings included increased secretory granule density in somatotroph cells and altered GH content and responsiveness in vitro following chronic ipamorelin exposure. The authors interpreted these findings as evidence of adaptive somatotroph remodeling following sustained GHS-R1a stimulation, contributing to the understanding of pituitary cell biology under repeated secretagogue exposure [6].

Pancreatic Insulin Secretion (2004)

Adeghate and Ponery (2004) examined the effects of ipamorelin on insulin secretion from isolated pancreatic tissue fragments obtained from normal and streptozotocin-diabetic rats [7]. In this in vitro preparation, ipamorelin was reported to evoke measurable insulin secretion from both normal and diabetic pancreatic tissue. Pharmacological inhibition studies using calcium channel blockers and adrenergic receptor antagonists were associated with attenuation of the observed secretion, leading the authors to propose calcium channel and adrenergic receptor pathway involvement in the pancreatic response [7]. The authors noted this was the first published characterization of ipamorelin's effects on pancreatic tissue, representing a novel direction for GHS-R1a biology research.

Rodent Postoperative Ileus Model: Gastrointestinal Transit (2009)

Venkova and colleagues (2009) evaluated ipamorelin in a rodent model of postoperative ileus (POI) in which male rats underwent laparotomy and intestinal manipulation [8]. Colonic transit was assessed using a dye marker in the proximal colon. Following single-dose intravenous administration, ipamorelin was associated with a reduction in time to first bowel movement. With repetitive dosing, ipamorelin was associated with significant changes in cumulative fecal output, food intake, and body weight gain compared to vehicle controls [8]. The authors noted that the results supported further investigation of ipamorelin in clinical postoperative settings, contributing to the rationale that informed subsequent human clinical investigation.

Gastric Dysmotility and Cholinergic Mechanism (2012)

Greenwood-Van Meerveld and colleagues (2012) extended the POI investigation to gastric function using both in vivo and ex vivo preparations in a rodent postoperative model [9]. In vivo, ipamorelin administration was associated with restoration of delayed gastric emptying observed following abdominal surgery. In isolated gastric tissue strips, surgical manipulation was associated with suppressed contractile responses to acetylcholine and electrical field stimulation; ipamorelin and natural ghrelin were both reported to normalize these contractile responses. The authors attributed the observed effects to GHS-R1a–mediated activation of cholinergic excitatory neurons in the enteric nervous system and characterized the findings as mechanistic support for the gastrointestinal research program [9].

Phase 2 Randomized Controlled Trial: Postoperative Ileus (2014)

Beck and colleagues (2014), on behalf of the Ipamorelin 201 Study Group, published results from a multicenter, double-blind, placebo-controlled, proof-of-concept phase 2 trial evaluating ipamorelin in 117 patients undergoing small or large bowel resection with primary anastomosis [10]. Patients received intravenous ipamorelin or placebo twice daily beginning on postoperative day 1 for up to seven days.

Ipamorelin was well tolerated in the study, with adverse event rates similar between groups. The median time to tolerating a solid meal was 25.3 hours in the ipamorelin group and 32.6 hours in the placebo group — a 7.3-hour difference that did not achieve statistical significance (p=0.15) on the primary composite gastrointestinal endpoint in this proof-of-concept cohort [10]. The trial authors noted the importance of the tolerability findings and the directional trend, while acknowledging that the primary endpoint was not met at statistical significance in this phase 2 investigation. The study provided a foundation of human safety and pharmacological data in a clinical setting, and its findings contributed to the understanding of ghrelin receptor agonist pharmacology in postoperative human subjects — including the demonstration that the compound was well tolerated in a surgical patient population.

Active Research Frontier

Several dimensions of the published ipamorelin literature remain open areas for future investigation.

Human data on ipamorelin's GH-releasing activity, hormonal selectivity profile, and pharmacokinetics in healthy subjects have not been published; the clinical literature is limited to the postoperative ileus patient population. Researchers sourcing material for preclinical investigation can review batch-specific analytical documentation for ipamorelin from SpartaLabs. The selectivity findings from conscious swine and rat models represent a well-characterized preclinical pharmacological observation whose translation to human neuroendocrine physiology is an area of ongoing scientific interest.

Species differences in GH secretory patterns, GHS-R1a expression distribution, and pituitary feedback regulation between rodents, swine, and humans are recognized considerations when interpreting the preclinical body of data. Characterization of ipamorelin in additional research models, and elucidation of the molecular basis for its selectivity profile, represent directions that could further define the compound's place within the GHS-R1a agonist pharmacological class.

The pancreatic insulin secretion data (Adeghate and Ponery, 2004) represent preliminary in vitro observations that have not been extended in intact animal models or clinical settings. Similarly, the bone growth findings from the 1999 Johansen study in rats have not been followed with studies in additional species or with mechanistic characterization at the IGF-1 axis level.

References

1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PMID: 9849822. DOI: 10.1530/eje.0.1390552

2. Ankersen M, Johansen NL, Madsen K, Hansen BS, Raun K, Nielsen KK, et al. A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. J Med Chem. 1998;41(19):3699-704. PMID: 9733495. DOI: 10.1021/jm9801962

3. Johansen PB, Hansen KT, Andersen JV, Johansen NL. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica. 1998;28(11):1083-92. PMID: 9879640. DOI: 10.1080/004982598238976

4. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-13. PMID: 10373343. DOI: 10.1054/ghir.1999.9998

5. Malmlöf K, Johansen PB, Haahr PM, Wilken M, Oxlund H. Methylprednisolone does not inhibit the release of growth hormone after intravenous injection of a novel growth hormone secretagogue in rats. Growth Horm IGF Res. 1999;9(6):445-50. PMID: 10629165. DOI: 10.1054/ghir.1999.0128

6. Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G. Influence of chronic treatment with the growth hormone secretagogue ipamorelin, in young female rats: somatotroph response in vitro. Histol Histopathol. 2002;17(3):707-14. PMID: 12168778. DOI: 10.14670/HH-17.707

7. Adeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuroendocrinol Lett. 2004;25(6):403-6. PMID: 15665799.

8. Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110-6. PMID: 19289567.

9. Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012;4:149-55. PMID: 27186127. DOI: 10.2147/JEP.S35396

10. Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34. PMID: 25331030. DOI: 10.1007/s00384-014-2030-8